AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT04880278
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Half of the participants (30 individuals) will receive placebo capsules that are opaque and contain only dextrose. Placebo capsules will be administered by mouth only once (around 120 minutes prior to fMRI scanning).
Trial: NCT05650411
Drug: P2Y12 inhibitor-based SAPT after short DAPT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Potent P2Y12 inhibitor-based SAPT (ticagrelor 90 mg bd, or prasugrel 5 or 10 mg od, at the discretion of the investigator) during 2 years. Aspirin stopped after LMCA or at latest at hospital discharge.
Trial: NCT05222516
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily administration of Placebo capsules
Trial: NCT06377761
Drug: Qishen Granules
FDA approved: no
EMA approved: no
PMDA approved: no
Description: One package per time, twice a day, 90 days of treatment
Trial: NCT06377761
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: One package per time, twice a day, 90 days of treatment (the placebo was basically the same as Qishen granules in terms of appearance, shape, color, taste, etc.)
Trial: NCT05556512
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered SC
Trial: NCT06241118
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pharmaceutical form: Injection solution Route of administration: Subcutaneous
Trial: NCT06241118
Drug: Topical corticosteroids
RxNorm normalized name: CORTICOSTEROIDS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pharmaceutical form: Various Topical formulation Route of administration: Topical
Trial: NCT05032157
Drug: LOU064 (blinded)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LOU064 (blinded) active treatment
Trial: NCT05032157
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo
Trial: NCT06781944
Drug: Cyclophosphamide (CTX)
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Participants in the control arm will receive cyclical cyclophosphamide and glucocorticoids.~Oral cyclophosphamide will be given for 30 days in month 2, 4, 6.~The dosage is adjusted based on the age and renal function (rounded down to the nearest 25 mg, max 100 mg/day, Cyclophosphamide tablets should not be split; if necessary, alternating doses of 50 mg/day and 100 mg/day can be used):~* 2.0 mg/kg/d in patients \< 65 years with eGFR ≥60ml/min~* 1.5 mg/kg/d in patients \< 65 years with eGFR\<60ml/min~* 1.5 mg/kg/d in patients ≥ 65 years with eGFR ≥60ml/min~* 1.0 mg/kg/d in patients ≥ 65 years with eGFR\<60ml/min
Trial: NCT06781944
Drug: Glucocorticoids
RxNorm normalized name: GLUCOCORTICOIDS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants in the control arm will receive cyclical cyclophosphamide and glucocorticoids.~Methylprednisolone 500 mg iv will be given for 3 consecutive days at the start of month 1,3,5 and followed by prednisone 0.5mg/kg/d (max 40mg/d) for 27 days.
Trial: NCT06782048
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will receive placebo by mouth once each day for a total of 14 days.
Trial: NCT05852002
Drug: 35 kDa hyaluronan fragment
RxNorm normalized name: PALMITOYL FRAGMENT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 mg of 35kDa hyaluronan fragment was injected deeply into abdominal fat layer once a day for 28 consecutive days.
Trial: NCT04670081
Drug: Nicotinamide
RxNorm normalized name: Nicotinamide
DrugBank: Nicotinamide (DB02701)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 100 mg, p.o.
Trial: NCT06738368
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IV
Trial: NCT06738368
Drug: Doxorubicin
RxNorm normalized name: Doxorubicin
DrugBank: Doxorubicin (DB00997)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given CIV
Trial: NCT06587685
Drug: Vehicle
RxNorm normalized name: Drug vehicle
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vehicle Gel twice daily for 8 weeks
Trial: NCT05306873
Drug: Placebo for Mycophenolate Mofetil
RxNorm normalized name: Mycophenolate Mofetil
DrugBank: Mycophenolate mofetil (DB00688)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Stage 2 Dosing:~Week 1: Participants will receive 500mg MMF/Placebo twice daily Week 2: Participants will receive 500mg/Placebo in the morning and 1,000mg MMF/Placebo in the evening Weeks 3-48: Participants will receive 1000mg MMF/Placebo twice daily
Trial: NCT05419583
Drug: Anticoagulants (Apixaban, Edoxaban, Rivaroxoban, Warfarin)
RxNorm normalized name: CPDA-1 Anticoagulant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anticoagulant therapy if atrial fibrillation identified (DOAC or Warfarin)
Trial: NCT05419583
Drug: Guideline directed heart failure therapy
RxNorm normalized name: porcine heart preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Use of guideline approved heart failure treatments (ACE-inhibitor / angiotensin receptor blocker (ARB) / ARB and neprilysin inhibitor, mineralocorticoid receptor antagonist, beta blocker, SGLT-2 inhibitor, diuretic therapy)
Trial: NCT05419583
Drug: Statins (Cardiovascular Agents)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Statins will be recommended for patients with coronary plaque disease or hypercholesterolaemia
Trial: NCT05486715
Drug: Vit D
RxNorm normalized name: Tri-Vit Drops
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vit D
Trial: NCT05206201
Drug: Placebo Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Two part study with single and multiple dose
Trial: NCT05707403
Drug: BI 1015550 mixed with [C-14]-BI 1015550
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment R
Trial: NCT05176314
Drug: Rosuvastatin
RxNorm normalized name: Rosuvastatin
DrugBank: Rosuvastatin (DB01098)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Administered Orally.
Trial: NCT04853368
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral capsules
Trial: NCT05751421
Drug: Zynrelef (Bupivacaine 60 MG / Meloxicam 1.8 MG) Per 2.3 ML Extended Release Solution
RxNorm normalized name: Zynrelef (bupivacaine 60 MG / meloxicam 1.8 MG) per 2.3 ML Extended Release Solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: zynrelef will be administered during surgery
Trial: NCT02738073
Drug: Control: Saline
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT04732494
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ociperlimab placebo injection is a sterile, preservative-free solution for infusion formulated in the same buffer as ociperlimab active drug.
Trial: NCT04840914
Drug: LY3461767
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered SC.
Trial: NCT04840914
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered SC.
Trial: NCT04455958
Drug: Placebo Administration
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Given PO
Trial: NCT03770663
Drug: Cyclophosphamide and azathioprine
RxNorm normalized name: Azathioprine
DrugBank: Azathioprine (DB00993)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: European strategy 6 IV pulses of Cyclophosphamide (1000mg) followed from M5 to M12 by oral Azathioprine (2mg/kg/day), with a maximum of 150mg/day
Trial: NCT06195072
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: see Experimental Arm intervention description
Trial: NCT06582706
Drug: Placebo Comparator
FDA approved: no
EMA approved: no
PMDA approved: no
Description: a readily available inert placebo will be used
Trial: NCT04680273
Drug: [14C]-GDC-9545
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will receive a single oral dose of \[14C\]-GDC-9545 capsule, 30 milligrams (mg) (not more than \[NMT\] 4.6 megabecquerel \[MBq\]; 124 microcurie \[μCi\]) with approximately 240 millilitres (mL) water in the fasted state.
Trial: NCT06480981
Drug: Noribogaine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Noribogaine capsules
Trial: NCT06245941
Drug: TQ05105 tablets
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TQ05105 is a Janus kinase 1 (JAK1) and Janus kinase 2 (JAK2) Inhibitor
Trial: NCT06245941
Drug: TQB3909 tablets
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TQB3909 is an inhibitor targeting B-cell lymphoma-2 (BCL-2) protein.
Trial: NCT05621070
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo will be administered per auto-injector. Participants will receive placebo every 2 weeks subcutaneously.
Trial: NCT05621070
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo will be administered per auto-injector. Participants will receive placebo every 4 weeks subcutaneously.
Trial: NCT05684055
Drug: First-line antihypertensive single-pill combination (SPC)
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: In intervention villages, participants diagnosed with aHT are offered pharmacological treatment (eHealth supported prescription of first-line antihypertensive single-pill combination (SPC)) and treatment monitoring in the villages by CC-VHWs guided by the ComBaCaL app.
Trial: NCT05156047
Drug: Double-blind placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching placebo tablets will be provided for each strength of active pitolisant film-coated tablets.
Trial: NCT06424756
Drug: MitoTempo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: During each experimental visit, intradermal microdialysis will be used to locally infuse MitoTempo (a mitochondria-specific superoxide dismutase mimetic) into the cutaneous microvasculature in the ventral aspect of the left forearm.
Trial: NCT05548556
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will receive subcutaneous (SC) placebo every 4 weeks (Q4W)
Trial: NCT04868760
Drug: IBI310
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Drug: IBI310 0.1 mg/kg and 0.3 mg/kg in preparatory experiments and 0.3 mg/kg in formal experiment.
Trial: NCT05993806
Drug: L04RD1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 tablet of L04RD1
Trial: NCT05993806
Drug: L04TD3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 tablet of L04TD3
Trial: NCT06789744
Drug: Intravenous Patient-Controlled Analgesia (PCA) (fentanyl)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: For intravenous PCA, a solution of fentanyl 2 mcg/kg will be diluted to a total volume of 100 mL with normal saline. The PCA settings will be as follows: a basal rate of 2 mL/hour, a PCA dose of 2 mL, and a lockout interval of 15 minutes.
Trial: NCT05773937
Drug: 9MW2821
FDA approved: no
EMA approved: no
PMDA approved: no
Description: All subjects will receive a single intravenous (IV) infusion of 9MW2821 once weekly for the first 3 weeks of every 4 week cycle (i.e., on Days 1, 8 and 15).
Trial: NCT06560489
Drug: Subjects will be randomly assigned to receive 1.25 mg, 2.5 mg, 5 mg, or 10 mg of LP-98.
FDA approved: no
EMA approved: no
PMDA approved: no
Description: This study consisted of 4 cohorts with 10 subjects in each group, who were randomly assigned to receive LP-98 treatment of 1.25 mg, 2.5 mg, 5 mg, and 10 mg. The method of administration was subcutaneous injection, and the interval of administration was 14 days, a total of 4 doses.
Trial: NCT05007236
Drug: RP7214 + Standard of care (SOC)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: RP7214 tablets will be administered orally twice a day for 14 days
Trial: NCT05007236
Drug: Placebo + Standard of care (SOC)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo will be administered orally twice a for 14 days
Trial: NCT05314621
Drug: olopatadine hydrochloride ophthalmic solution 0.7%)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pataday® Once Daily Relief Extra Strength (eyedrop)
Trial: NCT05314621
Drug: Saline nasal spray
RxNorm normalized name: Saline Nasal Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Saline nasal spray (nasal spray)
Trial: NCT05258721
Drug: ClōSYS® Sensitive Fluoride Toothpaste
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ClōSYS® Sensitive Fluoride Toothpaste is an over-the-counter drug product containing 0.12% stabilized chlorine dioxide (sodium chlorite in an aqueous solution) and 0.13% w/v fluoride ion.
Trial: NCT05415137
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo IV infusion every 4 weeks for a total of 12 doses
Trial: NCT04757766
Drug: in daily everyday routine practice
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The treatment of patients with chronic venous disease of CEAP classes C6 will be consistent with routine clinical practice, local label for the medical use of drugs and the specific clinical situation.
Trial: NCT04996160
Drug: Doxorubicin
RxNorm normalized name: Doxorubicin
DrugBank: Doxorubicin (DB00997)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 25 mg/m2/dose IV
Trial: NCT05977868
Drug: Amoxicillin, amoxicillin-clavulanate, cefadroxil, cefpodoxime, cefalexin, ciprofloxacin, delafloxacin, doxycycline, levofloxacin, linezolid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: COpAT (oral antimicrobial therapy) on hospital discharge
Trial: NCT03365414
Drug: Normal Saline 0.9% Infusion Solution Bag
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo Normal Saline 0.9% Infusion Solution Bag.
Trial: NCT05276063
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo taken twice daily by mouth
Trial: NCT05663710
Drug: ArabinoFuranosylGuanine [18F]F-AraG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Given by IV (vein)
Trial: NCT06512584
Drug: PJ009 Placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: subcutaneous injections, once daily
Trial: NCT04761302
Drug: Intravenous ketorolac and oral acetaminophen
RxNorm normalized name: phenylephrine and ketorolac
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ketorolac 30 mg intravenous (IV) every 6 hours for patients younger than 70 years versus ketorolac 15 mg IV every 6 hours for patients older than 70 years, first dose will be administered 30 minutes preoperatively. An additional 1000mg of oral acetaminophen will be administered every 6 hours simultaneously regardless of the age group
Trial: NCT05658003
Drug: ARDT
RxNorm normalized name: CHLAMYDOMONAS REINHARDTII
FDA approved: no
EMA approved: no
PMDA approved: no
Description: administered orally on a continuous basis, as per package insert and guidelines
Trial: NCT05658003
Drug: [68Ga]Ga-PSMA-11
FDA approved: no
EMA approved: no
PMDA approved: no
Description: single intravenous dose of approximately 150 MBq. Administered dose must not be lower than 111 MBq or higher than 259 MBq (3 - 7 mCi).
Trial: NCT05288283
Drug: GWP42003-P
RxNorm normalized name: P
FDA approved: no
EMA approved: no
PMDA approved: no
Description: oral solution
Trial: NCT05288283
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: oral solution
Trial: NCT05653258
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjects will receive a placebo (methylcellulose) to provide a similar mass, number of tablets/ capsules, and frequency as the senolytic arm.
Trial: NCT05509790
Drug: LY3484356
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered orally.
Trial: NCT06798038
Drug: phenol neurolysis
RxNorm normalized name: Phenol
DrugBank: Phenol (DB03255)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 35 Patients will be administered with 2.0 ml of 6% phenol solution prepared from crystallized phenol per genicular nerve
Trial: NCT06799650
Drug: Gammora®
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gammora® SC + Tenofovir/3TC + darunavir+ritonavir
Trial: NCT05781152
Drug: Anti-TNF therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Use of anti-TNF therapy for children and adolescents with newly diagnosed Crohn's disease guided by a clinical decision support tool
Trial: NCT06792474
Drug: Normal saline
RxNorm normalized name: Normal Saline Flush
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Normal saline infusion
Trial: NCT06787118
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients will receive placebo for a total of 12 weeks.
Trial: NCT05318534
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administration route: intravenous infusion and subcutaneous injection
Trial: NCT06785987
Drug: intermittent fentanyl infusion
RxNorm normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Maintained with volatile anesthetic gas (sevoflurane) and intermittent fentanyl infusion.
Trial: NCT06783868
Drug: Market-approved AVNB, OAC and AAD
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Used per protocol for the duration of the trial.
Trial: NCT06788366
Drug: Immunotherapy
RxNorm normalized name: Dog immunotherapy extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: First-line regimen according to clinical practice
Trial: NCT06788366
Drug: Chemotherapy
RxNorm normalized name: Chemotherapy Glove SML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: First-line regimen according to clinical practice
Trial: NCT06163989
Drug: TheaLoz Duo Eyedrop
RxNorm normalized name: Effaclar Duo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TheaLoz Duo lubricating eyedrop contains 3.0% trehalose and 0.15% sodium hyaluronate as active ingredients and will be used by participants everyday to instill 1 drop, 4 times a day in both eyes.
Trial: NCT06062030
Drug: DWJ1609
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Drug of test group
Trial: NCT06062030
Drug: DWC202304
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Drug of control group
Trial: NCT06792435
Drug: XNW27011
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Eligible patient(s) in each dose cohort will receive the assigned XNW27011 dose administration every 3 weeks (Q3W, cycle) until intolerable toxicity, progression of the disease without clinical benefit, or withdrawal of informed consent.~An accelerated titration scheme will be used for the first two dose levels (0.6 mg/kg and 1.2 mg/kg) starting from 0.6 mg/kg dose as follows:~The first patient will be enrolled for 0.6 mg/kg dose. If the subject shows no significant toxicity in cycle 1 (DLT observation period), the second patient will be enrolled for 1.2 mg/kg.~3 + 3 dose escalation:3 patients will be enrolled to the dose cohort first，If 1 of 3 patients experiences a DLT, up to 3 more patients will be enrolled in the same dose cohort.. If none of the additional 3 patients experiences a DLT, dose escalation will continue to the next dose.Dose escalation will be stopped when 2 or more patients out of 3 to 6 patients at the same dose level experience a DLT.
Trial: NCT06792435
Drug: XNW27011
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group A: Gastric/gastroesophageal junction adenocarcinoma with CLDN18.2 expression, tentatively expand with 3.6, 3.0, 2.4 mg/kg. Group B: Pancreatic adenocarcinoma with CLDN18.2 expression, tentatively expand with 3.6, 3.0, 2.4 mg/kg. Group C: Ovarian cancer with CLDN18.2 expression, tentatively expand with 3.6, 3.0, 2.4 mg/kg. Group D: Other tumors with CLDN18.2 expression, including but not limited to esophagus adenocarcinoma, lung cancer, colorectal cancer, and biliary tract cancer,tentatively expand with 3.6, 3.0, 2.4 mg/kg.
Trial: NCT06148272
Drug: LY3971297
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered SC
Trial: NCT06148272
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered SC
Trial: NCT05583526
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching capsule
Trial: NCT06784570
Drug: adrenaline,noreadrenaline,dopamine and doputamine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: adrenaline:\*4 9 %$ 0 \*\*\*\*8\*4\* 9 : ,- 4 - \*4 9 \* C % F\*4 9 9 9 noreadrenaline:# \*4 9 C % 9 F 9 9 \*4\* Q\*4 9 9 dopamine:9 \* C % 9 F 9 9 ) \* 9 9 dobutamine:9 \* C % F 9 9 9 \* 9 9
Trial: NCT06787885
Drug: Levofloxacin + clindamycin
RxNorm normalized name: Levofloxacin
DrugBank: Levofloxacin (DB01137)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Group 1
Trial: NCT05768360
Drug: Rosuvastatin
RxNorm normalized name: Rosuvastatin
DrugBank: Rosuvastatin (DB01098)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: The subjects will receive single dose of oral film-coated tablet of Rosuvastatin Dose E on Day 1 of Period 1 and Period 2 within 25 minutes \[+ 5 minutes\] from the start of meal.
Trial: NCT06447519
Drug: Ca(OH)2 as intracanal medicament
RxNorm normalized name: CITRUS MEDICA WHOLE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ca(OH2 will be used as intracanal medicament for the disinfection of the root canal between appointmnents
Trial: NCT06221150
Drug: Bilateral two level serratus anterior block
RxNorm normalized name: Fucus serratus extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A bilateral two-level SAPB will be performed with the guidance of ultrasound. While the patient is in the supine position with their arms abducted, the ribs will be counted down from the second rib at the level of manubriosternal joint, the mid- axillary line will be demarcated where the probe will be placed in the longitudinal plane to visualize the ribs and the overlying muscles. Using in- plane approach, a 22-gauge short bevel needle will be inserted and advanced to the plane between the latissimus dorsi muscle and the serratus muscle under sono-visualization at the level of 3rd and 6th ribs bilaterally in succession over which a total volume of 1ml/kg bupivacaine 0.25% will be divided and injected (0.5ml/kg on each side); with total dose not exceeding 2.5 mg/kg
Trial: NCT05760261
Drug: GSK3882347
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GSK3882347 will be administered.
Trial: NCT06310200
Drug: Bitrex
RxNorm normalized name: Bitrex
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bittering agent
Trial: NCT06310200
Drug: normal saline
RxNorm normalized name: Normal Saline Flush
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo
Trial: NCT05804591
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 capsule containing placebo per os 1 hour before start of the operation.